Table 2.
Cell lines used in the evaluation of antiproliferative activity.
| Cell line | Organ/disease | Origin tissue | Total growth inhibition (µg/mL) | |
|---|---|---|---|---|
| CE | DOX | |||
| U251 | CNS; glioma | Ectoderm | 26.10 | <0.025 |
| UACC-62 | Skin; melanoma | Ectoderm | 7.30 | 0.028 |
| NCI-ADR/RES∗ | Ovary; adenocarcinoma | Ectoderm | 26.40 | >25.00 |
| 786-O | Kidney; adenocarcinoma | Mesoderm | 28.00 | 0.038 |
| NCI-H460 | Lung; non-small-cell lung carcinoma | Mesoderm | 27.50 | <0.025 |
| PC-3 | Prostate; adenocarcinoma | Mesoderm | 24.80 | 0.025 |
| OVCAR-3 | Ovary; adenocarcinoma | Mesoderm | 4.40 | 0.230 |
| HT-29 | Colon; adenocarcinoma | Endoderm | 7.90 | 0.026 |
| K562 | Bone marrow; chronic myeloid leukemia | Mesenchyme | >250 | >25.00 |
Results are the mean ± SD of 3 replicates per treatment in three independent tests after 48 hours of treatment.
CE: crude extract of Amphipterygium adstringens.
DOX: doxorubicin (positive control).
∗Multidrug resistant cell line.